Over the past two weeks, several large drug makers have either halted or rolled back prices as political pressure mounts on the pharmaceutical industry.
The moves suggest more than a little political posturing because the Trump administration is trying to follow through on implementing its so-called blueprint for lowering drug costs and, presumably, these companies hope to get something in return.
That said, their moves, or at least the circumstances, vary somewhat. Here is a quick cheat sheet on what each company has agreed to do:
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
